ImpriMed Launches Innovative AI-Driven Drug Response Predictions (DRP) Service to Guide Tailored Treatments, Meet Rising Demand in Veterinary Oncology
In response to surging veterinary demand for personalized canine cancer testing, ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the launch of ImpriMed Drug Response Predictions (DRP) .
- In response to surging veterinary demand for personalized canine cancer testing, ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the launch of ImpriMed Drug Response Predictions (DRP) .
- DRP empowers veterinarians with AI-driven clinical outcome predictions for canines with lymphoma and leukemia tailored to individual patient needs, improving efficacy and accelerating patient treatment.
- Precision diagnostics enable patient-specific cancer therapies upfront, eliminating the need for costly and time-consuming wait-and-see approaches after drug administrations.
- “We’re thrilled to unveil ImpriMed Drug Response Predictions to fulfill growing customer demand for individualized testing and fundamentally transform clinical approaches to canine cancer treatment.